/

Empresas

Ne

No verificado

Neurim Pharmaceuticals

Sobre qué escribimos

EconomíaFarmacéuticaInfanciaSanidadStart-up

3 Comunicados de prensa

Ver todos los comunicados de prensa

26/03/2025

Farmacéutica

Sanidad

Infancia

NEURIM PHARMACEUTICALS RICEVE L'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO IN EUROPA PER LA MELATONINA A RILASCIO PROLUNGATO PEDIATRICA (SLENYTO®) PER IL TRATTAMENTO DELL'INSONNIA NEI BAMBINI AFFETTI DA DISTURBO DA DEFICIT DI ATTENZIONE E IPERATTIVITÀ (ADHD)

Fuente

Neurim Pharmaceuticals

Editor

1.00

0

26/03/2025

Farmacéutica

Sanidad

Infancia

NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Fuente

Neurim Pharmaceuticals

Editor

1.00

0

30/07/2024

Farmacéutica

Sanidad

Economía

Start-up

Infancia

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)

Fuente

Neurim Pharmaceuticals

Editor

1.00

0

Seguidores

0

Compatibilidad

0